NCT00148109View on ClinicalTrials.gov

Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

December 31, 2009

Conditions
Sarcoma
Interventions
DRUG

Cetuximab

The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.

DRUG

Cetuximab

Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min

Trial Locations (1)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER